Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Hookipa Pharma Inc
HOOKCurrent price
1.21 USD
-0.02 USD (-1.63%)
Last closed
1.25 USD
Company
www.hookipapharma.com
ISIN
US43906K1007
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
26 158 266 USD
Yield for 12 month
-82.78 %
1Y
3Y
5Y
10Y
15Y
HOOK
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-200 for the treatment of pembrolizumab which is in Phase 2 of clinical trial; HB-700, a preclinical development for treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers. Its lead product candidates are HB-400 for the treatment of Hepatitis B which is in Phase I of clinical trial and HB-500 for the treatment of HIV which is in Phase I of clinical trial. The company's preclinical stage products include HB-300 program for prostate cancer. It has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York. Address: 350 Fifth Avenue, New York, NY, United States, 10118
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
31.67 USDP/E ratio
–Dividend Yield
–Current Year
+20 129 000 USD
Last Year
+14 249 000 USD
Current Quarter
+4 703 000 USD
Last Quarter
+1 290 000 USD
Current Year
+16 577 000 USD
Last Year
+14 249 000 USD
Current Quarter
+4 703 000 USD
Last Quarter
+1 134 000 USD
Key Figures HOOK
1 year
3 years
5 years
10 years
EBITDA
-47 709 000 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-20.10 %
PEG Ratio
–
Return On Equity TTM
-48.99 %
Wall Street Target Price
31.67 USD
Revenue TTM
52 163 000 USD
Book Value
7.45 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-51.80 %
Dividend Yield
–
Gross Profit TTM
-52 966 000 USD
Earnings per share
-3.67 USD
Diluted Eps TTM
-3.67 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
-93.16 %
Dividend Analytics HOOK
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History HOOK
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
1:10
Payout Ratio
–
Last Split Date
10.07.2024
Stock Valuation HOOK
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
1.91
Price Sales TTM
0.50
Enterprise Value EBITDA
0.46
Price Book MRQ
0.36
Financials HOOK
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators HOOK
For 52 weeks
1.88 USD
11.30 USD
50 Day MA
3.27 USD
Shares Short Prior Month
39 538
200 Day MA
5.81 USD
Short Ratio
1.08
Shares Short
45 025
Short Percent
0.47 %
BeatStart